A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of RO7079901 Administered Intravenously Both Alone and in Combination With Meropenem in Adult Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Meropenem (Primary) ; Nacubactam (Primary) ; RO 7049389
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 20 Apr 2017 Status changed from recruiting to completed.
- 15 Mar 2017 Planned End Date changed from 1 Oct 2017 to 31 Oct 2017.
- 15 Mar 2017 Planned primary completion date changed from 1 Oct 2017 to 31 Oct 2017.